Amarin Corp. (AMRN) Misses Q3 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amarin (AMRN) Q4 'Very Strong', Seen as 'Great Tuck-In' for Big Pharma - Jefferies
February 27, 2019 12:52 PM ESTJefferies analyst Michael Yee weighed in on Amarin Corporation (NASDAQ: AMRN) following "very strong" Q4 results as the company is working hard to file the sNDA to expand the label by 10x to a broad CV population this quarter.
Yee notes... More
